Artificial Intelligence for the Detection of Diabetic Retinopathy in Primary Care: Protocol for Algorithm Development

Abstract

Background Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries. In diabetic patients, periodic examination of the back of the eye using a nonmydriatic camera has been widely demonstrated to be an effective system to control and prevent the onset of DR. Convolutional neural networks have been used to detect DR, achieving very high sensitivities and specificities. Objective The objective of this is paper was to develop an artificial intelligence (AI) algorithm for the detection of signs of DR in diabetic patients and to scientifically validate the algorithm to be used as a screening tool in primary care. Methods Under this project, 2 studies will be conducted in a concomitant way: (1) Development of an algorithm with AI to detect signs of DR in patients with diabetes and (2) A prospective study comparing the diagnostic capacity of the AI algorithm with respect to the actual system of family physicians evaluating the images. The standard reference to compare with will be a blinded double reading conducted by retina specialists. For the development of the AI algorithm, different iterations and workouts will be performed on the same set of data. Before starting each new workout, the strategy of dividing the set date into 2 groups will be used randomly. A group with 80% of the images will be used during the training (training dataset), and the remaining 20% images will be used to validate the results (validation dataset) of each cycle (epoch). During the prospective study, true-positive, true-negative, false-positive, and false-negative values will be calculated again. From here, we will obtain the resulting confusion matrix and other indicators to measure the performance of the algorithm. Results Cession of the images began at the end of 2018. The development of the AI algorithm is calculated to last about 3 to 4 months. Inclusion of patients in the cohort will start in early 2019 and is expected to last 3 to 4 months. Preliminary results are expected to be published by the end of 2019. Conclusions The study will allow the development of an algorithm based on AI that can demonstrate an equal or superior performance, and that constitutes a complement or an alternative, to the current screening of DR in diabetic patients. International Registered Report Identifier (IRRID) PRR1-10.2196/12539

Artificial Intelligence for Mental Health and Mental Illnesses: an Overview

“…A major strength of AI is rapid pattern analysis of large datasets. Areas of medicine most successful in leveraging pattern recognition include ophthalmology, cancer detection, and radiology, where AI algorithms can perform as well or better than experienced clinicians in evaluating images for abnormalities or subtleties undetectable to the human eye (e.g., gender from the retina) [16][17][18][19]. While it is unlikely that intelligent machines would ever completely replace clinicians, intelligent systems are increasingly being used to support clinical decision-making [8, 14••, 20].…”

Artificial intelligence and Psychiatry: An overview

“…As artificial intelligence is data science a huge strength of artificial intelligence is swift pattern analysis/ rapid screening of large datasets. Areas of medicine which have till now been most successful in using artificial intelligence for pattern recognition include ophthalmology, oncology, and radiology, where artificial intelligence algorithms have performed at par or even better in some instances compared to experienced clinicians in evaluating images for abnormalities or acuity undetectable to the human eye ( Brinker et al, 2019 , Hosny et al, 2018 , Vidal-Alaball et al, 2019 ).…”

The artificial intelligence revolution in primary care: Challenges, dilemmas and opportunities

“…In the management of diabetes, the use of algorithms for retinography reading support for screening diabetic retinopathy is well documented with sensitivities around 87–97% and specificities around 96–97%, 20 , 21 as well as for the detection of other ocular pathologies such as glaucoma and age-related macular degeneration. 20 …”